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Abstract
BACKGROUND: Vascular calcification (VC) is a risk factor for cardiovascular morbidity and mortality in maintenance 
hemodialysis (MHD) patients. The effect of alpha2-Heremans Schmid glycoprotein (AHSG) Thr256Ser gene 
polymorphism toward serum fetuin-A levels as one of the VC inhibitors in MHD patients is still unclear.
OBJECTIVE: This study aims to investigate the relationship between AHSG Thr256Ser gene polymorphism toward 
serum fetuin-A levels in MHD patients in Indonesia.
METHODS: The research study design used was cross-sectional. Serum fetuin-A levels were assessed by enzyme-
linked immunosorbent assay method, and polymerase chain reaction-restriction fragment length polymorphism 
determined AHSG Thr256Ser gene polymorphism. Multivariate linear regression analysis was used to analyze the 
factors related to serum fetuin-A levels. p < 0.05 was considered as statistically significant.
RESULTS: Median value of serum fetuin-A levels was 235.0 pg/ml (ranging 78–756) with mean 259.99 ± 119.36 pg/
ml. Out of 106 patients involved, the distribution of AHSG Thr256Ser genotype frequency was 54 (50.9%) respondents 
had CG genotype, 46.2% had CC genotype, and the others (2.8%) had GG genotype. Patients with homozygous C 
allele (CC genotype) were 0.1 times more protected (CI 95%: 0.1–0.3) to have low serum fetuin-A levels, compared 
with patients with G allele either in a homozygote (GG genotype) or in the heterozygote (CG genotype). From the 
multivariate analysis results, it can be obtained a formulation in predicting serum fetuin-A level, which is: Serum fetuin-A 
level prediction = 276,59 + 150,49 DM - 0,26 serum interleukin -6 level - 43,58 AHSG Thr256Ser gene polymorphism
CONCLUSIONS: AHSG Thr256Ser gene polymorphism had a significant relationship with serum fetuin-A levels in 
MHD patients in Indonesia. Subjects with G allele (CG and GG genotypes) had lower serum fetuin-A levels than 
those with CC genotype.
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Introduction
Cardiovascular disease (CVD) is found in 
>50% of patients undergoing dialysis. This disease is 
the primary cause of morbidity and mortality in end-
stage renal disease (ESRD) patients undergoing 
maintenance hemodialysis (MHD), where the hazard 
ratio for death caused by this CVD is 20 times higher 
than in general populations [1].
One of the cardiovascular risk factors in HD 
patients is vascular calcification (VC) [1]. There are 
two types of VC in patients with chronic kidney disease 
(CKD), which include intima calcification and medial 
calcification (Monckenberg’s medial sclerosis). Both 
of these calcifications have different complications. 
Intima calcification is related to atherosclerotic plaque, 
causing blood vessel occlusion; on the other hand, 
medial calcification provokes blood vessel stiffness [2].
The pathogenesis of VC is complex and is 
not fully understood yet [2]. In vitro study showed that 
VC process is not just simple deposition of calcium 
phosphate crystals, but is a process similar to bone 
osteogenesis. This process involves vascular smooth 
muscle cells (VSMCs) transdifferentiation to cells 
resembling bone progenitor cells [1]. VC process 
is an active process but can be modified, although 
VSMCs gradually experience apoptosis and vesicle 
formation changing VSMCs phenotype into osteoblast 
cells that can undergo mineralization process. Several 
VC inhibitors have been investigated, such as matrix 
GLA protein, osteoprotegerin, pyrophosphates, and 
fetuin-A [2].
Fetuin-A also is known as alpha 2-Heremans 
Schmid glycoprotein (AHSG) is a part of the cystatin 
family from cysteine protease inhibitors. Fetuin-A 
interacts with the small mineral core to form dissolved 
colloid particles so that basic calcium phosphate (BCP) 
deposition does not happen and works as a calcification 
inhibitor in a concentrated extracellular environment. As 
a result, fetuin-A can prevent calcification in circulation 
without intervening normal bone mineralization. 
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Furthermore, in the cellular level, fetuin-A inhibits 
apoptosis from VSMCs and helps binding apoptosis 
bodies with surrounding cells aiming toward cleaning 
and thus lowering potential to form BCP [2].
In CKD patients, serum fetuin-A levels 
are lower than healthy control subjects [2]. Three 
fetuin-A genotypes can probably be seen, which are 
Thr/Thr (C allele), Thr/ser (heterozygous), and Ser/
Ser (G allele). In several kinds of literature, it is said 
that there is a relationship between serum levels and 
gene polymorphism coding fetuin-A [3]. Stevinkel 
et al., satetes that Dialysis patients in Sweden 
showed lower serum fetuin-A levels in fetuin-A 
Thr256Ser [4]. As well as Axelsson et al. concluded 
that fetuin-A (C→G), Thr256Ser gene polymorphism 
affected circulation serum fetuin-A levels. On the 
contrary, another study found that fetuin-A (C→G) 
distribution, gene polymorphism did not affect serum 
fetuin-A levels [2]. Due to this contradiction, this 
research was conducted to determine whether there 
is a relationship between AHSG Thr256Ser gene 
polymorphism toward serum fetuin-A levels in regular 
HD patients in Indonesia.
Methods
Study design
This study was a cross-sectional study involving 
106 regular hemodialysis (HD) patients in the HD unit 
in Rumah Sakit Khusus Ginjal Rasyida. This study 
was conducted from January to May 2018. Patients 
included in this study were ≥18 years old, undergoing 
HD ≥30 months, and were willing to participate by 
signing informed consent. Patients with liver diseases, 
active infections, and malignancy were excluded from 
the study. Helsinki’s Declaration was conducted in this 
study.
Assessments
Personal information and medical history 
(such as age, gender, race, smoking history, DM, 
hypertension, CVD, malignancy, and duration of HD) 
were obtained through medical records and interviews. 
Calculation of body mass index (BMI) was collected 
by measuring weight in kilograms divided by height in 
meter square. Consequently, blood drawing, routine, 
and particular tests were performed. Routine tests 
included calcium, phosphate, and albumin. Specific 
tests performed were quantitative fetuin-A test and 
DNA extraction as well as functional fetuin-A genotype 
polymorphism test. Five milliliters venous blood would 
be drawn from each patient in the morning after the 
patient fasted at night before blood was drawn. Five 
hundred micro whole blood would be separated in 
an Eppendorf containing ethylenediaminetetraacetic 
acid 5% and was kept in −20° for Thr256Ser testing 
using polymerase chain reaction (PCR) technique. The 
remaining samples would go into disposable tubes and 
were left to clot, then were put into centrifuge machine 
at 1200 rpm for 10–15 min to separate serum. Serum 
was divided into three aliquots and was frozen. Serum 
fetuin-A quantitative and interleukin-6 (IL-6) testing 
were assessed by enzyme-linked immunosorbent 
assay (ELISA) method.
Statistical analysis
Research data were analyzed using Statistical 
Package for the Social Sciences version program 
(SPSS program version 22.0 SPSS Inc., Chicago, IL, 
USA). Normality test by Kolmogorov–Smirnov was put 
into use. Numeric data were displayed as median and 
range as mean±standard deviation. Categorical data 
were demonstrated in n (percent). To compare serum 
fetuin-A levels with patient’s characteristics, the Mann–
Whitney U-test was used. If data are coming from more 
than three groups/populations, then the Kruskal–Wallis 
test was put into use. To see the comparison of HD 
patients characteristics based on serum fetuin-A levels, 
Chi-square test was used for categorical-categorical 
variables and Mann–Whitney U-test for categorical-
numerical variables. If expected count value <5, as 
a result, Fisher’s exact test was adapted. Correlation 
between variables was assessed with Spearman 
correlation or Pearson’s coefficient correlation. p-value 
was said to be significant if < 0.05 (p < 0.05).
Results
Samples characteristics
Out of 106 respondents, 65 subjects (61.3%) 
were male and the remaining 41 subjects (38.7%) were 
female. Patients aged between 21 and 78 years old with 
53.89 ± 11.44 years old. Patients on average underwent 
HD for the 1st time at age 48.19 ± 12.79 years old. Most 
patients went through HD for 10 h in 1 week (73.6%) 
and typically had been going through HD for 69.44 ± 
34.57 months (range 34–237). Average respondents’ 
BMI was overweight (24.22 ± 4.09 kg/m2).
Through ELISA method, median serum fetuin-A 
levels and IL-6 were obtained which were 235.0 pg/ml 
(range 78–756) and 70.7 pg/ml (range 25.4–898.0) with 
mean 259.99 ± 119.36 pg/ml and 99.64 ± 115.51 pg/
ml. On the other hand, AHSG Thr256Ser genotype 
frequency was collected by PCR-restriction fragment 
length polymorphism test with the result such as 
54 (50.9%) respondents had CG genotypes, 46.2% 
of respondents had CC genotypes, and the remaining 
(2.8%) had GG genotypes.
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The relationship between various factors 
with serum fetuin-A levels
The comparison of serum fetuin-A levels based 
on HD patients characteristics is shown in Table 1. 
Statistical analysis significantly showed that patients 
with DM had a higher mean (407.6 ± 176.6 pg/ml) and 
higher median (331 pg/ml) serum fetuin-A levels than 
in patients without DM (p < 0.001). As well as, patients 
whose serum IL-6 <70.7 pg/ml and albumin ≥3.9 mg/
dL had higher mean and median serum fetuin-A levels 
compared with patients with serum IL-6 ≥70.7 pg/ml 
and albumin <3.9 mg/dL (p < 0.001 and p = 0.03).
Table 1: Comparison of serum fetuin-A levels based on HD 
patients characteristics
Variables Serum fetuin-A levels p
Mean ± SD Median (range)
Age (years)
<60 260.3 ± 128.5 232.5 (78–756) 0.25#
≥60 259.4 ± 102.5 237.5 (113–725)
HD vintage (months)
<60 265.9 ± 129.3 231 (113–756) 0.52#
≥60 253.1 ± 107.6 242 (78–723)
DM
No 219.1 ± 45.5 227 (78–328) <0.001#
Yes 407.6 ± 176.6 331 (207–756)
Klasifikasi IMT
Underweight – normal 266.0 ± 120 238 (111–746) 0.28#
Overweight – obese 245.3 ± 117 229 (78–756)
Serum calcium (mg/dL)
≤9.5 268.3 ± 152.9 227 (111–746) 0.33#
>9.5 254.3 ± 90.5 238 (78–756)
Serum phosphate (mg/dL)
≤5.5 251.5 ± 105.1 233 (111–725) 0.69#
>5.5 269.9 ± 134.5 235 (78–756)
Serum IL-6 (pg/ml)
<70.7 322.4 ± 138.8 270.0 (191–756) <0.001#
≥70.7 197.6 ± 39.4 208.0 (78–253)
Serum albumin (mg/dL)
<3.9 232.4 ± 97.2 228.0 (78–723) 0.03#
≥3.9 279.6 ± 130.1 241.5 (112–756)
Polymorphism
CC genotype 319.1 ± 147.8 266.0 (184–756) <0.001*
CG genotype 214.1 ± 43.5 216.5 (111–328)
GG genotype 120.3 ± 4.5 113.0 (78–170)
#Mann–Whitney U-test, *Kruskal–Wallis test. HD: Hemodialysis, IL: Interleukin.
Statistical test significantly showed that 
patients with CC genotypes had the highest mean and 
median serum fetuin-A levels, while patients with GG 
genotypes had the lowest mean and median serum 
fetuin-A levels (p < 0.001) compared with the other 
AHSG gene genotypes.
Figure 1 shows that patients with DM had higher 
mean and median serum fetuin-A levels compared with 
patients without DM (p < 0.001).
To determine the power correlation between 
serum IL-6 level and serum fetuin-A level, Spearman’s 
rho correlation test was put into test. Figure 2 shows 
that serum fetuin-A had a significant negative 
correlation with serum IL-6 level, which means that the 
higher serum IL-6 level, the lower serum fetuin-A level. 
R = 0.9 showed that the power correlation between two 
variables was powerful.
Figure 2: Correlation between serum interleukin -6 level and serum 
fetuin-A level
HD patient characteristics based on serum 
fetuin-A level are shown in Table 2. Statistical test 
significantly showed that group of patients with low 
serum fetuin-A level was dominated by patients 
without DM (60.2%) (p < 0.001), had serum IL-6 
≥70.7 pg/ml (86.8%) (p < 0.001) and serum albumin 
<3.9 mg/dL (61.4%) (p = 0.03). Furthermore, based 
on its AHSG gene polymorphism, it can be seen that 
more patients with GG genotypes had lower serum 
Figure 1: The comparison of serum fetuin-A levels based on DM 
comorbidity
Table 2: Characteristics of MHD patients based on serum 
fetuin-A levels
Variables Serum fetuin-A levels p PR 95% CI
Low (n=52) High (n=54)
Age (years)
<60 35 (51.5) 33 (48.5) 0.51* 1.2 0.8–1.8
≥60 17 (44.7) 21 (55.3)
HD vintage (months) 
<60 30 (52.6) 27 (47.4) 0.43* 1.3 0.9–1.9
≥60 22 (44.9) 27 (55.1)
DM
No 50 (60.2) 33 (39.8) <0.001* 7.0 1.8–26.4
Yes 2 (8.7) 21 (91.3)
IMT (kg/m2)
Underweight – normal 35 (46.7) 40 (53.3) 0.44* 1.2 0.8–1.8
Overweight – obese 17 (54.8) 14 (45.2)
Serum calcium (mg/dL)
≤9.5 23 (43.4) 30 (56.6) 0.24* 1.6 0.7–3.4
>9.5 29 (54.7) 24 (45.3)
Serum phosphate (mg/dL)
≤5.5 29 (50.9) 28 (49.1) 0.53* 1.1 0.7–1.6
>5.5 23 (46.9) 26 (53.1)
Serum IL-6 (pg/ml)
<70.7 6 (11.3) 47 (88.7) <0.001* 6.7 3.3–13.5
≥70.7 46 (86.8) 7 (13.2)
Serum albumin (mg/dL)
<3.9 27 (61.4) 17 (38.6) 0.03* 2.4 1.1–5.2
≥3.9 25 (40.3) 37 (59.7)
Polymorphism, n (%)
CC genotype 12 (24.5) 37 (75.55) <0.001* 0.1 0.1–0.3
CG genotype 37 (68.5) 17 (31.5)
GG genotype 3 (100.0) 0 (0.0)
CC genotype 12 (24.5) 37 (75.55)
CG+GG genotype 40 (70.2) 17 (29.8)
*Chi-square, #Mann–Whitney U, ^Fisher’s exact. MHD: Maintenance hemodialysis, HD: Hemodialysis, 
IL: Interleukin.
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fetuin-A levels compared with the other groups of 
subjects (p < 0.001).
From this table, it can also be concluded that 
lower serum fetuin-A levels were 7.0 times (CI 95%: 
1.8–26.4) more likely occurred in patients without DM, 
6.7 times (CI 95%: 3.3–13.5) in patients with serum 
IL-6 ≥70.7 pg/ml and 2.4 times (CI 95%: 1.1–5.2) in 
patients with serum albumin <3.9 mg/dL. Patients 
who had homozygous C allele (CC genotype) were 
0.1 times (CI 95%: 0.1–0.3) more protected to have low 
serum fetuin-A level, compared with patients who had 
either homozygous (GG genotype) or heterozygous 
(CG genotype) G allele.
Figure 3 showed that an individual with GG 
genotype was correlated  with low serum fetuin-A levels 
and high serum IL-6 levels. In other words, there is 
an inverse relationship between serum IL-6 level and 
serum fetuin-A level in every AHSG gene genotype.
Figure 3: The effect of alpha 2-Heremans Schmid glycoprotein 
Thr256Ser gene polymorphism toward serum fetuin-A and IL-6 levels
To determine the variables affecting serum 
fetuin-A levels significantly, multivariate analysis on 
variables was performed with p ≤ 0.25 in a previously 
performed bivariate test. Variables that were included in 
the multivariate test include age when first undergoing 
HD, duration of HD, DM, serum IL-6, albumin, and 
AHSG gene polymorphism.
According to the statistical test, it was 
concluded that DM (p < 0.001), serum IL-6 (p < 0.001), 
and Thr256Ser polymorphism (p = 0.001) were 
significant factors related to serum fetuin-A levels. Out 
of that table, a formula can be created in predicting 
serum fetuin-A levels as follows:
Predicted serum fetuin-A level = 320.49 + 
150.49 DM - 0.26 serum IL-6 level - 43.58 polymorphism
Slope value for DM variable was +150.49, which 
means that every increase of one unit DM increased 
serum fetuin-A as much as 150.49. An increase of one 
unit implied that there was an alternation from without 
DM into with DM. On the other hand, slope value for 
polymorphism was −43.58, which means for every 
increase of one unit polymorphism lowered serum 
fetuin-A levels as much as 43.58. It is meant as one unit 
increased was changes from C allele (CC genotype) 
becoming G allele (CG+GG genotype).
Discussion
CKD is related to the increased risk of CVD. 
ESRD patients with dialysis have death risk 10–20 times 
higher caused by CVD complications compared with 
the general populations. VC is a strong independent 
risk factor contributing to mortality caused by CVD. 
VC can cause arterial stiffness, an increase in blood 
pressure, left ventricle hypertrophy, and death as a 
result of CVD [2].
Blood vessel changes observed in CKD 
patients who are not only atherosclerosis but also wide 
arteriosclerosis related to VC on both media and intima. 
Blood vessel stiffness and the extent of calcification 
are considered as prognosis predictor of death in HD 
patients. This extensive calcification is considered 
linked to the decrease in calcification inhibitor or blood 
vessel protection factor such as fetuin-A [3]. In CKD 
patients, serum fetuin-A levels are significantly lower 
than in control subjects [2].
Fetuin-A is a glycoprotein weighing 64-kDa that 
has a relatively high concentration in human’s serum 
(300–1000 µg/ml). Fetuin-A plays a role as VC inhibitor. 
As a result, it can inhibit calcium-phosphate deposition. 
Fetuin-A inhibits ectopic calcification of mineral by 
obstructing the formation of apatite to prevent mineral 
precipitation [2].
This study observed the relationship between 
fetuin-A and its gene in patients undergoing HD. 
AQ6,7Table 3: Multivariate analysis of factors related to serum 
fetuin-A levels at the final step
Model Variables Adjusted R2 B p
1 Intercepts 52.4% 369.41 0.003
DM 149.63 <0.001
Serum IL-6 −0.28 <0.001
Serum albumin −20.20 0.45
Polymorphism −46.46 0.01
HD duration 0.38 0.11
Age −0.68 0.35
2 Intercepts 52.6% 283.70 <0.001
DM 149.52 <0.001
Serum IL-6 −0.26 0.001
Polymorphism −45.05 0.01
HD duration 0.37 0.12
Age −0.59 0.41
3 Intercepts 52.7% 252.75 <0.001
DM 148.81 <0.001
Serum IL-6 −0.26 0.001
Polymorphism −44.01 0.02
HD duration 0.35 0.14
4 Intercepts 52.1% 320.49 <0.001
DM 150.49 <0.001
Serum IL-6 ≥70.7 pg/ml −0.26 0.001
Polymorphism −43.58 0.02
*Linear regression test, HD: Hemodialysis, IL: Interleukin. AQ8
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A higher number of patients with GG genotypes (91.2%) 
had lower serum fetuin-A levels compared with the 
other group of subjects (p < 0.001). Group of patients 
with CC genotype had the highest mean and median 
serum fetuin-A levels. Maharem et al. attempted to 
understand the pathogenesis of VC increased risk 
by analyzing Thr256Ser gene polymorphism in CKD 
patients with conservative therapy, HD and those 
who had undergone kidney transplantation and had 
them compared with healthy control subjects. They 
did not find any difference between the three fetuin-A 
genotypes (C→G) in all groups. However, fetuin-A 
distribution (C→G); Thr256Ser gene polymorphism 
showed a significant relation with how low the serum 
fetuin-A levels were, where subjects with CG and GG 
genotypes had lower serum fetuin levels than patients 
with CC genotype [2]. Axelson et al. displayed the same 
result. They found that circulating serum fetuin-A level 
was affected by fetuin-A Thr256Ser gene polymorphism 
(C-G) [5]. On the contrary, Cozzolino et al., in Italy, and 
Zeidan et al. concluded that both in HD patients and 
control group, fetuin-A gene distribution did not show 
correlation with serum fetuin-A level [6], [7].
To understand serum fetuin-A genetic control, 
Jensen et al. conducted genome-wide association 
meta-analysis research on six populations, as part 
of Cohorts for Heart and Aging Research in Genomic 
Epidemiology consortium. AHSG expression is 
controlled by several transcriptional factors (TFs) 
including C/EBP-[beta], NF-1, HNF-3[beta], AP-1, 
and ER [alpha]. SNP rs2248690, which is located 
on the promoter, has a strong association with 
serum fetuin-A level, modifies AHSG transcription 
by changing AP-1 affinity. Although located at the 
end of AHSG region, this variant undergoes linkage 
disequilibrium with SNPs 4917 and rs4918 located 
on exon (r2 > 0.80 CEU) that has the potential to 
disrupt DNA chains on some TFs, including AP-1 
and ER[alpha]. A transcription complex consisting of 
ERα and AP-1 can contribute to AHSG transcription 
induced by estrogen.
On the other hand, controlling function coming 
from a coding location that saves rs4917 and rs4918 
needs further studies. They get rs4917 and rs4918 as 
missense variant located at the two last exons from the 
AHSG gene (each exon 6 and 7 has the same effect 
on the difference of serum fetuin-A level in the plasma). 
This study concluded that a genetic variant on the AHSG 
gene is strongly associated with serum fetuin-A levels. 
However, it cannot be excluded that there is a chance 
of other genetic loci playing a role in determining the 
fetuin-A concentration [8].
The underlying and mechanism of low serum 
fetuin-A levels in GG genotype compared within CC 
genotype have not been fully understood. The difference 
in results in several studies before can be explained by 
variation in the race and the effect of fetuin-A nucleotide 
polymorphism toward its serum level [2].
In this research, there were a higher mean 
and median serum fetuin-A levels in patients with DM 
than in patients without DM. Statistical test significantly 
showed that patients without DM had 7 times more 
risks (CI 95 %: 1.8–26.4) to have lower serum fetuin 
A levels. Verdujin et al. followed 1043 dialysis patients 
with Thr256Ser genotype polymorphism (rs4918) 
for 5 years, then measured serum fetuin-A levels 
in 549 patients and concluded that one of the risk 
factors for low serum fetuin-A levels was diabetes and 
inflammation [9]. Maharem et al. also obtained the same 
result, where patients with DM had higher mean and 
median serum fetuin-A level than in patients without DM 
(p < 0.001) [2]. Srinivas et al. first proved 20 years ago 
that fetuin-A was linked to insulin receptor at tyrosine 
kinases. The liver and adipose tissue secrete fetuin-A. 
Serum fetuin-A levels correlate with various metabolic 
parameters, such as insulin sensitivity, glucose 
tolerance, lipid level, and pro- and anti-inflammatory 
protein levels [10]. AHSG gene polymorphism has 
been associated with DM type 2 prevalence. AHSG 
gene is located at chromosome 3q27, which has 
been identified as loci region susceptible to metabolic 
syndrome. Fetuin-A inhibits tyrosine kinase receptor 
activity in skeletal muscle and hepatocytes, and thus, 
it inhibits insulin signal transduction. As a result, insulin 
resistance occurs in target tissues. Because of that, 
in general population, fetuin-A correlates with insulin 
resistance, metabolic syndrome and is an independent 
risk factor toward DM type 2 [2], [11], [12].
Nonetheless, in the uremic environment, how 
the metabolic syndrome is linked to increased serum 
fetuin-A level which is far more complex. Although 
genetically, Mendelian random observational study 
predicted that serum fetuin-A level did not have 
an association with diabetes prevalence, diabetes 
incidence, or fasting glucose. However, the limitation of 
this study was that it did not count non-esterified fatty 
acid level, where recently it showed interaction with 
fetuin-A to predict the degree of insulin resistance [10].
The presence of CC genotype in an individual 
will increase serum fetuin-A level and decrease serum 
IL-6 level. There is a contradictory relation between 
serum IL-6 and serum fetuin-A levels in every AHSG 
gene genotype. To determine correlation power between 
serum IL-6 and serum fetuin-A, a correlation test was 
put into use. It significantly showed that the higher the 
serum IL-6 level was then, the lower the serum fetuin-A 
level was r = −0.9, p < 0.001. Inflammation is an integral 
component of atherosclerosis that can worsen damage 
by decreasing fetuin-A synthesis and other calcification 
inhibitors factors [2]. Lebreton et al. proved that fetuin-A 
expression arranged opposite by pro-inflammatory 
cytokines such as TNF-α, IL-1, and IL-6, because of 
that fetuin-A is classified as negative acute-phase 
protein. The serum concentration lowers during acute 
inflammation response and becomes normal when the 
infection is successfully handled. Memoli et al. reported 
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that IL-6 significantly induced suppression of fetuin-A 
expression in human’s hepatocytes [11].
Serum fetuin-A levels in HD patients showed a 
positive correlation with serum albumin [13]. Stavinkel 
et al. and Hamano et al. also discovered the relationship 
between fetuin-A and albumin [2]. In accordance with 
the previous research, bivariate test showed that 
research subjects who had serum albumin ≥3.9 mg/dL 
had higher mean (279.6 ± 130.1 pg/ml) and median 
(241.5 pg/ml) serum fetuin-A levels compared with 
patients who had serum albumin <3.9 mg/dL (p = 0.03). 
However, on the multivariate test, this result was not 
consistent anymore. Hypoalbuminemia that has a strong 
association with fetuin-A deficiency shows involvement 
of malnutrition-inflammation-atherosclerosis syndrome 
in fetuin-A deficiency [14]. Either albumin or fetuin-A, 
both produced in the liver, is an important protein that 
has various functions. This protein decreases when 
there are inflammation and malnutrition [15].
Conclusions
Fetuin-A plays an essential role in inhibiting 
calcification, especially in CKD patients. This research 
proved that AHSG Thr256Ser gene polymorphism had 
a significant association with serum fetuin-A levels 
in regular HD patients in Indonesia. Subjects with G 
allele (CG and GG genotype) had lower serum fetuin 
level compared with patients with CC genotype. The 
underlying and mechanism of low fetuin levels in GG 
genotype compared with CC genotype have not been 
fully understood yet. This can be caused by the difference 
in race and the effect or other fetuin-A nucleotide 
polymorphisms which were not analyzed in this study.
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